medigraphic.com
ISSN 2992-8036 (Electronic)
ISSN 2306-4102 (Print)
Órgano Oficial del Colegio Mexicano de Ortopedia y Traumatología

2012, Number 2

<< Back Next >>

Acta Ortop Mex 2012; 26 (2)

Adjuvant treatment with phenol of aggressive benign and low grade malignant bone tumors in patients with immature skeleton

Vaquerizo V, Abril JC, Ramírez A, Montes E

Language: Spanish
References: 32
Page: 107-111
PDF size: 78.75 Kb.


ABSTRACT

Introduction: The surgical treatment of aggressive benign bone tumors is based on intralesional resection associated with local adjuvant treatment to avoid local relapses. The purpose of this study is to assess the effectiveness of adjuvant treatment with phenol in aggressive, low grade, malignant and benign bone tumors in young patients. Material and methods: We conducted a descriptive retrospective study of 37 patients, 13 girls and 24 boys, with bone tumors. They were treated with curettage and intralesional phenol between January 1989 and January 2006. The study included 35 Campanacci grade III benign tumors and 2 low grade malignant tumors, Enneking IA. Results: Minimum follow-up was 5 years. The local relapse rate was 13.5%. Mean age at the time of surgery was 10.7 years (SD ± 4.4). Mean patient follow-up was 104.9 months (SD ± 41.9). Mean time between surgery and relapse was 18.8 months (SD ± 11.81). Complications during the follow-up period occurred in 18.9% of the patients. The MSTS score was 28.7 points (SD ± 1.7). Discussion: The treatment of bone tumors with phenol shows low relapse and complication rates, so it is indicated for the management of locally aggressive bone tumors.


REFERENCES

  1. Atalar H, Basarir K, Yildiz Y, Erekul S, Saglik Y: Management of chondroblastoma: retrospective review of 28 patients. J Orthop Sci 2007; 12(4): 334-40.

  2. Calvo E, Abril JC, Galovich L, Ferrer A, Ferrer M: Consideraciones sobre el tratamiento de los condrosarcomas diferenciados. Rev Ortop Traum 1993; 37(Supl 2): 23-7.

  3. Rock M: Adjuvant management of benign tumors; basic concepts of phenol and cement use. Chir Organi Mov 1990; 75(Suppl 1): 195-7.

  4. Saiz P, Virkus W, Piasecki P, Templeton A, Shott S, Gitelis S: Results of giant cell tumor of bone treated with intralesional excision. Clin Orthop Relat Res 2004; (424): 221-6.

  5. Durr HR, Maier M, Jansson V, Baur A, Refior HJ: Phenol as an adjuvant for local control in the treatment of giant cell tumor of the bone. Eur J Surg Oncol 1999; 25(6): 610-8.

  6. Quint U, Müller RT, Müller G: Characteristics of phenol. Instillation in intralesional tumor excision of chondroblastoma, osteoclastoma and enchondroma. Arch Orthop Trauma Surg 1998; 117: 43-6.

  7. Trieb K, Bitzan P, Lang S, Dominkus M, Kotz R: Recurrence of curetted and bone-grafted giant-cell tumors with and without adjuvant phenol therapy. Eur J Surg Oncol 2001; 27(2): 200-2.

  8. Bini SA, Gill K, Johnston JO: Giant cell tumor of bone. Curettage and cement reconstruction. Clin Orthop 1995; 321: 245-50.

  9. Marcove RC: A 17-year review of cryosurgery in the treatment of bone tumors. Clin Orthop Relat Res 1982; (163): 231-4.

  10. O’Donnell RJ, Springfield DS, Motwani HK, Ready JE, Gebhardt MC, Mankin HJ: Recurrence of giant-cell tumors of the long bones after curettage and packing with cement. J Bone Joint Surg Am 1994; 76(12): 1827-33.

  11. Schreuder HW, Pruszczynski M, Veth RP, Lemmens JA: Treatment of benign and low-grade malignant intramedullary chondroid tumors with curettage and cryosurgery. Eur J Surg Oncol 1998; 24: 120-6.

  12. Campanacci M, Baldini N, Boriani S, Sudanese A: Giant-cell tumor of bone. J Bone Joint Surg (Am) 1987; 69: 106-14.

  13. Enneking WF: A system of staging musculoskeletal neoplasms. Clin Orthop Relat Res 1986; (204): 9-24.

  14. Enneking WF, Dunham W, Gebhardt MC, et al: A system for the functional evaluation of reconstructive procedures after surgical treatment of tumors of the musculoskeletal system. Clin Orthop 1993; 286: 241-6.

  15. Capanna R, Fabbri N, Bettelli G: Curettage of giant cell tumor of bone. The effect of surgical technique and adjuvant on local recurrence rate. Chir Organi Mov 1990; 75(Suppl 1): 206.

  16. Gitelis S, Mallin B, Piasecki P, Turner F: Intralesional excision compared with en bloc resection for giant cell tumors of bone. J Bone Joint Surg 1993; 75A: 1648-55.

  17. Blackley HR, Wunder JS, Davis AM, et al: Treatment of giant cell tumors of long bones with curettage and bone grafting. J Bone Joint Surg 1999; 81A: 811-20.

  18. Capanna R, Sudanese A, Baldini N, Campanacci M: Phenol as an adjuvant in the control of local recurrence of benign neoplasms of bone treated by curettage. Ital J Orthop Traumatol 1985; 11: 381-8.

  19. Lack W, Lang S, Brand G: Necrotizing effect of phenol on normal tissues and on tumors. Acta Orthop Scand 1994; 65: 351-4.

  20. Lin PP, Thenappan A, Deavers MT, Lewis VO, Yasko AW: Treatment and prognosis of chondroblastoma. Clin Orthop Relat Res 2005; 438: 103-9.

  21. Gibbs CP Jr, Hefele MC, Peabody TD, Montag AG, Aithal V, Simon MA: Aneurysmal bone cyst of the extremities. Factors related to local recurrence after curettage with a high-speed burr. J Bone Joint Surg Am 1999; 81(12): 1671-8.

  22. Jones KB, De Young BR, Morcuende JA, Buckwalter JA: Ethanol as a local adjuvant for giant cell tumor of bone. Iowa Orthop J 2006; 26: 69-76.

  23. Turcotte RE, Wunder JS, Isler MH, et al: Giant cell tumor of long bone: a Canadian sarcoma group study. Clin Orthop 2002; 397: 248-58.

  24. Lampasi M, Magnani M, Donzelli O: Aneurysmal bone cysts of the distal fibula in children: long-term results of curettage and resection in nine patients. J Bone Joint Surg Br 2007; 89(10): 1356-62.

  25. Oh JH, Yoon PW, Lee SH, Cho HS, Kim WS, Kim HS: Surgical treatment of giant cell tumor of long bone with anhydrous alcohol adjuvant. Int Orthop 2006; 30(6): 490-4.

  26. Zhitnikov A, Mazhuga PM: Changes in the metabolism of chondrocytes after chronic intake of phenol and lead. Arkh Anat Gistol Embriol 1986; 90(1): 72-6.

  27. Ramírez AR, Stanton RP: Aneurysmal bone cyst in 29 children. J Pediatr Orthop 2002; 22(4): 533-9.

  28. Suneja R, Grimer RJ, Belthur M, Jeys L, Carter SR, Tillman RM, Davies AM. Chondroblastoma of bone: long-term results and functional outcome after intralesional curettage. J Bone Joint Surg Br 2005; 87(7): 974-8.

  29. Bauer HC, Brosjo O, Kreicbergs A, Lindholm J: Low risk of recurrence of enchondroma and low-grade chondrosarcoma in extremities: 80 patients followed for 2-25 years. Acta Orthop Scand 1995; 66: 283-8.

  30. Ozaki T, Lindner N, Hillmann A, Rodl R, Blasius S, Winkelmann W: Influence of intralesional surgery on treatment outcome of chondrosarcoma. Cancer 1996; 77: 1292-7.

  31. Tsuchiya H, Ueda Y, Morishita H, Nonomura A, Kawashima A, Fellinger EJ, Tomita K: Borderline chondrosarcoma of long and flat bones. J Cancer Res Clin Oncol 1993; 119: 363-8.

  32. Lackman RD, Hosalkar HS, Ogilvie CM, Torbert JT, Fox EJ: Intralesional curettage for grades II and III giant cell tumors of bone. Clin Orthop Relat Res 2005; 438: 123-7.




2020     |     www.medigraphic.com